Biotech Startup Basecamp Research Raises $140M in Series C Funding

The round also saw participation from Anthropic’s Anthology Fund, Catalio Capital Management, European Tech Collective, Firebrand River Capital, Inception Fund, King Philanthropies, NATO Innovation Fund, NVIDIA, PostScriptum, Redalpine, The Rockefeller Foundation, Singular, Sovereign AI, and True Ventures.

The company will use the funding to expand its operations and continue developing its AI platform and therapeutic programs.

What is Basecamp Research?

Basecamp Research combines AI models trained on biological data with technology designed to write DNA sequences into cells.

The company is developing therapies that aim to reprogram cells inside the body. Its work focuses on in vivo cell therapy with potential applications in areas including cancer and autoimmune diseases.

Read More:California-Based Numeral Raises $100M in Series C Funding

Its EDEN biological foundation models are designed to understand patterns across DNA and other biological systems. The models can be used to design potential cell and gene therapies, enzymes, and peptides.

How Much Funding Has Basecamp Research Raised?

Basecamp Research has raised $140 million in its latest Series C funding round. The source does not provide details of its previous funding rounds or total funding raised.

Why the Funding Matters

Basecamp Research plans to use the new capital to expand its operations and development efforts.

The company is applying its EDEN models to in vivo cell therapy, where a patient's cells could potentially be reprogrammed inside the body.

Basecamp says its technology could help make cell therapies more complex and customizable while simplifying how they are administered.

Who founded Basecamp Research?

Basecamp Research was founded in 2019 by Glen Gowers and Oliver Vince. The company is headquartered in London, UK.

Leadership Comments

"We believe the future of medicine lies in reprogramming the body to repair itself. We design the models and the medicines to teach it how," said Glen Gowers, co-founder and CEO of Basecamp Research. "AI-based approaches promise to change what's possible for patients who currently have few alternatives.

Market and Business Growth

Basecamp Research has developed the Trillion Gene Atlas, which it describes as the world's largest proprietary biological AI training dataset.

The dataset was built with partners including NVIDIA, Anthropic, PacBio, and Ultima Genomics and includes biological data collected through access and benefit-sharing partnerships in more than 30 countries across all seven continents.

The company's EDEN models are trained on this data and are designed to identify patterns across previously unseen biology. The models have been used to generate potential therapeutic candidates and support work on cell and gene therapies, enzymes, and peptides.

Basecamp Research has also collaborated with Anthropic on Claude Science.

What Happens Next?

Basecamp Research plans to continue developing its EDEN AI models and therapeutic pipeline. Its work will focus on advancing in vivo cell therapy and developing potential treatments for diseases including cancer and autoimmune conditions as the company moves toward clinical development.

Read More:AI Startup Fearn Raises $5.5M in Funding Round